# Navigator Medicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/navigator-medicines

- Industry: Biotechnology
- Headquarters: Scotch Plains, US
- Website: www.navigatormedicines.com
- Total disclosed funding: $50M
- Latest round: Series A (Aug 23, 2024)
- Investors on record: 2

## About

Founded in 2024 and based in New Jersey, US, Navigator Medicines, Inc. offers immune regulation and treatments for autoimmune diseases. In August 2024, RA Capital Management and Forbion co-led a USD 100 million series A funding for Navigator Medicines, Inc.

The company’s product pipeline includes a biologics immune portfolio, NAV-240, formerly known as IMB101, a clinical-stage bispecific antibody designed to target OX40L and TNFa. The product improves health by addressing two distinct yet interrelated mechanisms of inflammation and immune response. 

The company will use the August 2024 funding to develop NAV-240 and advance its pipeline of OX40L-targeted mono- and bispecific antibodies.

## Funding rounds

- Series A, Aug 23, 2024, $50M — Forbion, RA Capital Management

## Investors

- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A